• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.影响骨代谢的药物在预防髋部骨折方面疗效的证据。
BMJ. 1992 Nov 7;305(6862):1124-8. doi: 10.1136/bmj.305.6862.1124.
2
Hip fracture in Italy: epidemiology and preventive efficacy of bone-active drugs.
Bone. 1993;14 Suppl 1:S81-4. doi: 10.1016/8756-3282(93)90356-f.
3
Therapeutic strategies in the prevention of hip fracture with drugs affecting bone metabolism.
Bone. 1993;14 Suppl 1:S85-7. doi: 10.1016/8756-3282(93)90357-g.
4
The epidemiology of hip fractures and methods of prevention.髋部骨折的流行病学及预防方法。
Acta Orthop Belg. 1994;60 Suppl 1:85-101.
5
Hip fracture patients are not treated for osteoporosis: a call to action.髋部骨折患者未接受骨质疏松症治疗:行动呼吁。
Arthritis Rheum. 2002 Dec 15;47(6):651-4. doi: 10.1002/art.10787.
6
Osteoporosis. An update on management.骨质疏松症。管理方面的最新进展。
Drugs. 1984 Dec;28(6):565-76. doi: 10.2165/00003495-198428060-00005.
7
[Drug treatment of osteoporosis (in the woman)].[骨质疏松症的药物治疗(针对女性)]
Ther Umsch. 1998 Nov;55(11):696-701.
8
The vitamin D endocrine system, calcium metabolism, and osteoporosis.维生素D内分泌系统、钙代谢与骨质疏松症。
Spec Top Endocrinol Metab. 1983;5:83-148.
9
Pathogenesis and management of primary osteoporosis.原发性骨质疏松症的发病机制与管理
Clin Pharm. 1986 Aug;5(8):639-59.
10
Characteristics of lifetime factors, bone metabolism, and bone mineral density in patients with hip fracture.髋部骨折患者的终生因素、骨代谢及骨密度特征
J Bone Miner Metab. 2002;20(6):367-75. doi: 10.1007/s007740200053.

引用本文的文献

1
Calcitonin: A useful old friend.降钙素:一位有用的老朋友。
J Musculoskelet Neuronal Interact. 2020 Dec 1;20(4):600-609.
2
Bio-structural monitoring of bone mineral alterations through electromechanical impedance measurements of a Piezo-device joined to a tooth.通过连接到牙齿的压电装置的机电阻抗测量对骨矿物质改变进行生物结构监测。
Biomed Eng Lett. 2020 Sep 20;10(4):603-617. doi: 10.1007/s13534-020-00170-9. eCollection 2020 Nov.
3
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations.降钙素与骨生理学:体外、体内及临床研究
Int J Endocrinol. 2020 Sep 10;2020:3236828. doi: 10.1155/2020/3236828. eCollection 2020.
4
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.欧洲绝经后妇女骨质疏松症的诊断和管理指南。
Osteoporos Int. 2013 Jan;24(1):23-57. doi: 10.1007/s00198-012-2074-y. Epub 2012 Oct 19.
5
Oral calcitonin.口服降钙素。
Curr Osteoporos Rep. 2012 Mar;10(1):80-5. doi: 10.1007/s11914-011-0084-x.
6
Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels--an observational study during clinical practice conditions.维生素 D 补充的常用推荐剂量是否过低?维生素 D 状况和补充对血清 25-羟维生素 D 水平的影响——临床实践条件下的观察性研究。
Osteoporos Int. 2011 Jan;22(1):231-40. doi: 10.1007/s00198-010-1214-5. Epub 2010 Jun 17.
7
Progress in osteoporosis and fracture prevention: focus on postmenopausal women.骨质疏松症和骨折预防的进展:关注绝经后妇女。
Arthritis Res Ther. 2009;11(5):251. doi: 10.1186/ar2815. Epub 2009 Oct 14.
8
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.欧洲绝经后女性骨质疏松症诊断与管理指南。
Osteoporos Int. 2008 Apr;19(4):399-428. doi: 10.1007/s00198-008-0560-z. Epub 2008 Feb 12.
9
Salmon calcitonin: a review of current and future therapeutic indications.鲑鱼降钙素:当前及未来治疗适应证综述
Osteoporos Int. 2008 Apr;19(4):479-91. doi: 10.1007/s00198-007-0490-1. Epub 2007 Dec 11.
10
Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study.激素替代疗法的使用与骨折风险相关问题:一项基于人群的巢式病例对照研究。
Br J Clin Pharmacol. 2008 Jan;65(1):123-9. doi: 10.1111/j.1365-2125.2007.02904.x. Epub 2007 Oct 22.

本文引用的文献

1
Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen.绝经后使用雌激素可降低髋部和前臂下端骨折的风险。
N Engl J Med. 1980 Nov 20;303(21):1195-8. doi: 10.1056/NEJM198011203032102.
2
Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.司坦唑醇治疗绝经后骨质疏松症:治疗效果及可能的作用机制
Metabolism. 1983 Jun;32(6):571-80. doi: 10.1016/0026-0495(83)90027-6.
3
Treatment of osteoporotic fracture.
Lancet. 1984 Jan 7;1(8367):27-33. doi: 10.1016/s0140-6736(84)90191-0.
4
Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain.英国股骨近端骨折患者的体力活动、肌肉力量及钙摄入量
BMJ. 1988 Dec 3;297(6661):1443-6. doi: 10.1136/bmj.297.6661.1443.
5
Long-term estrogen replacement therapy prevents bone loss and fractures.长期雌激素替代疗法可预防骨质流失和骨折。
Ann Intern Med. 1985 Mar;102(3):319-24. doi: 10.7326/0003-4819-102-3-319.
6
Calcitriol treatment is not effective in postmenopausal osteoporosis.
Ann Intern Med. 1989 Feb 15;110(4):267-74. doi: 10.7326/0003-4819-110-4-267.
7
Calcium supplementation of the diet--I.饮食中的钙补充——I
BMJ. 1989 Jan 21;298(6667):137-40. doi: 10.1136/bmj.298.6667.137.
8
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.氟化物治疗对绝经后骨质疏松症女性骨折率的影响。
N Engl J Med. 1990 Mar 22;322(12):802-9. doi: 10.1056/NEJM199003223221203.
9
Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study.激素替代疗法与首次髋部骨折风险。一项基于人群的前瞻性队列研究。
Ann Intern Med. 1990 Jul 15;113(2):95-103. doi: 10.7326/0003-4819-113-2-95.
10
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.间歇性周期性依替膦酸治疗绝经后骨质疏松症。
N Engl J Med. 1990 Jul 12;323(2):73-9. doi: 10.1056/NEJM199007123230201.

影响骨代谢的药物在预防髋部骨折方面疗效的证据。

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

作者信息

Kanis J A, Johnell O, Gullberg B, Allander E, Dilşen G, Gennari C, Lopes Vaz A A, Lyritis G P, Mazzuoli G, Miravet L

机构信息

Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School.

出版信息

BMJ. 1992 Nov 7;305(6862):1124-8. doi: 10.1136/bmj.305.6862.1124.

DOI:10.1136/bmj.305.6862.1124
PMID:1463947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1883704/
Abstract

OBJECTIVE

To examine the effects of taking drugs affecting bone metabolism on the risk of hip fracture in women aged over 50 years.

DESIGN

Retrospective, population based, case-control study by questionnaire.

SETTING

14 centres in six countries in southern Europe.

SUBJECTS

2086 women with hip fracture and 3532 control women matched for age.

MAIN OUTCOME MEASURES

Number of drugs affecting bone metabolism taken and length taken for.

RESULTS

Women taking drugs affecting bone metabolism had a significantly decreased risk of hip fracture. After adjustment for differences in other risk factors, the relative risk of hip fractures was 0.55 (95% confidence interval 0.31 to 0.85) in women taking oestrogens, 0.75 (0.60 to 0.94) in those taking calcium, and 0.69 (0.51 to 0.92) in those taking calcitonin. The fall in risk was not significant for anabolic steroids (0.6 (0.29 to 1.22)). Neither vitamin D nor fluorides were associated with a significant decrease in the risk of hip fracture. The effect on hip fracture risk increased significantly with increasing duration of exposure (risk ratio 0.8 (0.61 to 1.05) for less than median exposure v 0.66 (0.5 to 0.88) for greater than median exposure). Drugs were equally effective in older and younger women, with the exception of oestrogen.

CONCLUSIONS

Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture. Short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fracture.

摘要

目的

研究服用影响骨代谢药物对50岁以上女性髋部骨折风险的影响。

设计

基于人群的回顾性病例对照问卷调查研究。

地点

南欧六个国家的14个中心。

研究对象

2086例髋部骨折女性和3532例年龄匹配的对照女性。

主要观察指标

服用影响骨代谢药物的数量及服用时间。

结果

服用影响骨代谢药物的女性髋部骨折风险显著降低。在对其他危险因素差异进行调整后,服用雌激素的女性髋部骨折相对风险为0.55(95%置信区间0.31至0.85),服用钙的女性为0.75(0.60至0.94),服用降钙素的女性为0.69(0.51至0.92)。合成代谢类固醇的风险降低不显著(0.6(0.29至1.22))。维生素D和氟化物均未与髋部骨折风险的显著降低相关。随着暴露时间延长,对髋部骨折风险的影响显著增加(暴露时间低于中位数者风险比为0.8(0.61至1.05),高于中位数者为0.66(0.5至0.88))。除雌激素外,药物在老年和年轻女性中效果相同。

结论

雌激素、钙和降钙素可显著降低髋部骨折风险。在骨质疏松自然病程后期进行短期干预可能对髋部骨折发生率有显著影响。